IDEAYA to report uveal melanoma trial results April 13

April 10, 2026 4:05 PM

IDEAYA Biosciences Inc. (NASDAQ: IDYA) will announce topline results from its Phase 2/3 OptimUM-02 trial on April 13, 2026, the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found